Cargando…
Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU). OmAb’s mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune urticari...
Autores principales: | Serrano-Candelas, Eva, Martínez-Aranguren, Rubén, Vega, Olga, Gastaminza, Gabriel, Bartra, Joan, Audicana, Maria Teresa, Núñez-Córdoba, Jorge M., Algorta, Jaime, Valero, Antonio, Martin, Margarita, Ferrer, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566209/ https://www.ncbi.nlm.nih.gov/pubmed/28827590 http://dx.doi.org/10.1038/s41598-017-09361-4 |
Ejemplares similares
-
Profile of omalizumab in the treatment of chronic spontaneous urticaria
por: Labrador-Horrillo, Moises, et al.
Publicado: (2015) -
Omalizumab for chronic urticaria in Latin America
por: Wilches, Paul, et al.
Publicado: (2016) -
Urticaria and angioedema as possible reactions of omalizumab
por: Ozbagcivan, Ozlem, et al.
Publicado: (2018) -
Randomized, double-blind, placebo-controled clinical trial of sublingual immunotherapy in natural rubber latex allergic patients
por: Gastaminza, Gabriel, et al.
Publicado: (2011) -
OMALIZUMAB IN TREATMENT-RESISTANT CHRONIC SPONTANEOUS URTICARIA
por: Godse, Kiran V
Publicado: (2011)